A recent report on gastric cancer demonstrated that how human epidermal growth factor receptor-2 (HER2) heterogeneity complicated the TIME is essentially regulated by the STING signaling pathway, whereas HER2-high areas remain immunologically inactivated [81]. This evidence concerns the gene ERBB2 and gastric cancer.